Clinical Trial Update: Trilaciclib Prior to Chemotherapy Plus Tislelizumab as 1L Treatment for Advanced Squamous Non-Small-Cell Lung Cancer [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial update evaluating trilaciclib given before chemotherapy plus tislelizumab as a first-line treatment for advanced squamous non-small cel…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Squamous Non-small Cell Lung Cancer

Drugs mentioned

• Tislelizumab (tislelizumab)
• trilaciclib (trilaciclib)

Snippet

Sponsor: Sichuan University | Conditions: Advanced Squamous Non-Small-Cell Lung Cancer | Phase 2 | Status: UNKNOWN